2335206
Cooperative Agreement
Overview
Grant Description
Sttr Phase II: Ultrasonic product release-testing equipment for the design, development, and advanced continuous manufacturing of pharmaceutical tablets.
The broader impact of this Small Business Technology Transfer (STTR) Phase II project is potentially profound and could offer a transformative approach to quality assurance in pharmaceutical manufacturing that directly targets medicine supply chain vulnerabilities and cost structure in the United States.
It aims to modernize the quality testing of the most widely used pharmaceutical dosage form—tablets—through rapid ultrasonic testing techniques and innovative automation/robotics.
This advancement may reduce the risk of quality failures, drug shortages, and recalls, ensuring more reliable access to essential medications for the public.
Nearly 70% of Americans rely on prescription drugs, with a significant portion of these medications currently produced overseas.
The project's commercial impact is in its potential to redefine quality assurance practices in the pharmaceutical industry, leading to improved efficiency, reduced costs, and enhanced product safety.
Such improvements can contribute to national health security by reducing dependence on unreliable foreign drug manufacturing.
Its societal benefits include improved healthcare outcomes through more dependable drug availability.
Furthermore, the project offers significant educational benefits, providing hands-on training and research opportunities for students in advanced manufacturing technologies.
The project focuses on inclusivity, attracting underrepresented groups into engineering, and fostering diversity in advanced research and innovation in pharmaceutical manufacturing.
The proposed project aims to address the critical gap in the pharmaceutical manufacturing industry regarding the outdated quality assurance methods and equipment currently employed in producing compressed pharmaceutical tablets.
The primary research objectives are to develop and validate innovative ultrasonic quality assurance and testing equipment that enables rapid, non-destructive, real-time release testing of pharmaceutical tablets.
This NSF STTR II project seeks to overcome the limitations of existing manufacturing and quality assurance technologies by employing novel approaches and associated mathematical modeling techniques, including machine learning (ML), to analyze tablet microstructures for quality assurance.
The research involves detailed mathematical modeling of the interactions between ultrasonic waves and the viscoelastic properties of tablet materials, leveraging both first-principles physics and ML-based modeling approaches.
The anticipated technical results include the development of a reliable, cost-effective solution for the pharmaceutical industry, enhancing the quality assurance process for tablet manufacturing through improved accuracy, efficiency, and scalability.
The project represents a significant advancement in the field, supporting the FDA's initiatives towards continuous manufacturing, quality by design, and process analytical technology.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are planned for this award.
The broader impact of this Small Business Technology Transfer (STTR) Phase II project is potentially profound and could offer a transformative approach to quality assurance in pharmaceutical manufacturing that directly targets medicine supply chain vulnerabilities and cost structure in the United States.
It aims to modernize the quality testing of the most widely used pharmaceutical dosage form—tablets—through rapid ultrasonic testing techniques and innovative automation/robotics.
This advancement may reduce the risk of quality failures, drug shortages, and recalls, ensuring more reliable access to essential medications for the public.
Nearly 70% of Americans rely on prescription drugs, with a significant portion of these medications currently produced overseas.
The project's commercial impact is in its potential to redefine quality assurance practices in the pharmaceutical industry, leading to improved efficiency, reduced costs, and enhanced product safety.
Such improvements can contribute to national health security by reducing dependence on unreliable foreign drug manufacturing.
Its societal benefits include improved healthcare outcomes through more dependable drug availability.
Furthermore, the project offers significant educational benefits, providing hands-on training and research opportunities for students in advanced manufacturing technologies.
The project focuses on inclusivity, attracting underrepresented groups into engineering, and fostering diversity in advanced research and innovation in pharmaceutical manufacturing.
The proposed project aims to address the critical gap in the pharmaceutical manufacturing industry regarding the outdated quality assurance methods and equipment currently employed in producing compressed pharmaceutical tablets.
The primary research objectives are to develop and validate innovative ultrasonic quality assurance and testing equipment that enables rapid, non-destructive, real-time release testing of pharmaceutical tablets.
This NSF STTR II project seeks to overcome the limitations of existing manufacturing and quality assurance technologies by employing novel approaches and associated mathematical modeling techniques, including machine learning (ML), to analyze tablet microstructures for quality assurance.
The research involves detailed mathematical modeling of the interactions between ultrasonic waves and the viscoelastic properties of tablet materials, leveraging both first-principles physics and ML-based modeling approaches.
The anticipated technical results include the development of a reliable, cost-effective solution for the pharmaceutical industry, enhancing the quality assurance process for tablet manufacturing through improved accuracy, efficiency, and scalability.
The project represents a significant advancement in the field, supporting the FDA's initiatives towards continuous manufacturing, quality by design, and process analytical technology.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH PHASE II (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE II", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23516
Grant Program (CFDA)
Awarding Agency
Place of Performance
Potsdam,
New York
13676-3202
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Termination This cooperative agreement was reported as terminated by the Department of Government Efficiency (DOGE) in July 2025. See All
Amendment Since initial award the End Date has been shortened from 08/31/26 to 04/25/25.
Amendment Since initial award the End Date has been shortened from 08/31/26 to 04/25/25.
Pharmacoustics Technologies was awarded
Cooperative Agreement 2335206
worth $997,734
from in September 2024 with work to be completed primarily in Potsdam New York United States.
The grant
has a duration of 7 months and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Cooperative Agreement was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase II Programs (SBIR/STTR Phase II).
SBIR Details
Research Type
STTR Phase II
Title
STTR Phase II: Ultrasonic Product Release-Testing Equipment for the Design, Development, and Advanced Continuous Manufacturing of Pharmaceutical Tablets
Abstract
The broader impact of this Small Business Technology Transfer (STTR) Phase II project is potentially profound and could offer a transformative approach to quality assurance in pharmaceutical manufacturing that directly targets medicine supply chain vulnerabilities and cost structure in the United States. It aims to modernize the quality testing of the most widely used pharmaceutical dosage form—tablets—through rapid ultrasonic testing techniques and innovative automation/robotics. This advancement may reduce the risk of quality failures, drug shortages, and recalls, ensuring more reliable access to essential medications for the public. Nearly 70% of Americans rely on prescription drugs, with a significant portion of these medications currently produced overseas. The project’s commercial impact is in its potential to redefine quality assurance practices in the pharmaceutical industry, leading to improved efficiency, reduced costs, and enhanced product safety. Such improvements can contribute to national health security by reducing dependence on unreliable foreign drug manufacturing. Its societal benefits include improved healthcare outcomes through more dependable drug availability. Furthermore, the project offers significant educational benefits, providing hands-on training and research opportunities for students in advanced manufacturing technologies. The project focuses on inclusivity, attracting underrepresented groups into engineering, and fostering diversity in advanced research and innovation in pharmaceutical manufacturing.
The proposed project aims to address the critical gap in the pharmaceutical manufacturing industry regarding the outdated quality assurance methods and equipment currently employed in producing compressed pharmaceutical tablets. The primary research objectives are to develop and validate innovative ultrasonic quality assurance and testing equipment that enables rapid, non-destructive, real-time release testing of pharmaceutical tablets. This NSF STTR II project seeks to overcome the limitations of existing manufacturing and quality assurance technologies by employing novel approaches and associated mathematical modeling techniques, including machine learning (ML), to analyze tablet microstructures for quality assurance. The research involves detailed mathematical modeling of the interactions between ultrasonic waves and the viscoelastic properties of tablet materials, leveraging both first-principles physics and ML-based modeling approaches. The anticipated technical results include the development of a reliable, cost-effective solution for the pharmaceutical industry, enhancing the quality assurance process for tablet manufacturing through improved accuracy, efficiency, and scalability. The project represents a significant advancement in the field, supporting the FDA’s initiatives towards continuous manufacturing, Quality by Design, and Process Analytical Technology.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
PT
Solicitation Number
NSF 23-516
Status
(Complete)
Last Modified 5/19/25
Period of Performance
9/1/24
Start Date
4/25/25
End Date
Funding Split
$997.7K
Federal Obligation
$0.0
Non-Federal Obligation
$997.7K
Total Obligated
Activity Timeline
Transaction History
Modifications to 2335206
Additional Detail
Award ID FAIN
2335206
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
Q3MXF165G6H9
Awardee CAGE
8GZS5
Performance District
NY-21
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Modified: 5/19/25